Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.
Med Clin North Am. 2024 Sep;108(5):911-921. doi: 10.1016/j.mcna.2024.03.006. Epub 2024 Apr 21.
For more than 20 years, the mainstay of pharmacologic treatment for depression and anxiety disorders has been serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors. There are newer medications, many with novel mechanisms of action, that have come to market; however, first-line treatments remain the same. There are now more robust data on the use of various augmentation agents in the treatment of major depressive disorder providing better recommendations for use by the primary care provider. Data to support the use of psychedelic-assisted psychotherapy in the treatment of mood and anxiety disorders are not robust enough to recommend generalized use at this time.
二十多年来，抗抑郁药和抗焦虑药物的主要治疗方法一直是选择性 5-羟色胺再摄取抑制剂和选择性 5-羟色胺和去甲肾上腺素再摄取抑制剂。虽然有许多具有新颖作用机制的新型药物已经上市，但一线治疗方法仍然相同。目前，关于各种增效剂在治疗重度抑郁症中的应用有更多的可靠数据，为初级保健提供者的使用提供了更好的建议。目前，支持使用迷幻药辅助心理疗法治疗情绪和焦虑障碍的数据还不够充分，无法推荐广泛使用。
